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We have established spontaneously immortalized Schwann cell lines from normal adult mice and rats and murine disease
models. One of the normal mouse cell lines, IMS32, possesses some biological properties of mature Schwann cells and high
proliferativeactivities. TheIMS32cells underhyperglycemic and/orhyperlipidemic conditionshavebeen utilized toinvestigatethe
pathogenesis of diabetic neuropathy, especially the polyol pathway hyperactivity, glycation, increased oxidative stress, and reduced
synthesisofneurotrophic factors.Inaddition to the mousecell lines,ourcurrent study focuses onthe characterizationofa normal
rat cell line, IFRS1, under normal and high glucose conditions. These Schwann cell lines can be valuable tools for exploring the
detailed mechanisms leading to diabetic neuropathy and novel therapeutic approaches against that condition.
1.Introduction
During the development and regeneration of the peripheral
nervoussystem(PNS),Schwanncellsareresponsibleforpro-
viding trophic support for the growth and maintenance of
neurons and ensheathing their axons in either a myelinating
or an unmyelinating form [1]. Schwann cell abnormalities as
aresultofhyperglycemiacanbeacauseofnervedysfunction,
such as reduced nerve conduction velocity, axonal atrophy,
and impaired axonal regeneration [2, 3]. In addition to the
hyperglycemia-related mechanisms of nerve injury, recent
experimental and clinical studies suggest that dyslipidemia
due to obesity and type 2 diabetes can play a role in
the development and progression of peripheral neuropathy
[4, 5]. Although the detailed pathogenesis remains unclear,
metabolic alterations in Schwann cells under hyperglycemic
and/or hyperlipidemic conditions appear to be, at least in
part, associated with polyol pathway hyperactivity, glycation
of cellular proteins and lipids, increased oxidative stress,
altered protein kinase C activity, and reduced supply of
neurotrophic factors [3–8]. Moreover, impaired lipid and
cholesterol metabolism in Schwann cells under diabetic con-
ditions may aﬀect the structure and function of peripheral
myelins [9, 10].
Cultured Schwann cells can be valuable tools for explor-
ing the pathogenesis of diabetic neuropathy and the strategy
foritspreventionandtreatment. Sincesome biologicalprop-
erties of Schwann cells change with maturation and aging
[11, 12], culture systems of mature Schwann cells appear
to mimic diabetic neuropathy and other neurodegenerative
diseases better than those of immature cells. Compared with
a considerable number of articles on Schwann cells from
embryonic and neonatal animals [13, 14]; however, far fewer
studies have been made with primary cultures of Schwann
cells from adult animals [15, 16]. One of the reasons for
this seems to be problems in isolation of Schwann cells from
mature peripheral nerves; fully developed epineurium and
perineurium with substantial amounts of connective tissue
make it diﬃcult and time consuming to get good yields
of Schwann cells and suﬃciently eliminate ﬁbroblasts from
the culture. To avoid such a long process of the primary
culture, many investigators have established cell lines from2 Experimental Diabetes Research
Schwannoma cells(e.g.,JS1[17,18])and long-termcultured
Schwann cells by transfection of oncogenes such as SV40
large T antigen (e.g., MS1 [19]) or by spontaneous immor-
talization [20–22]. These lined cells rapidly proliferate to
increase the cell number and are more suitable for molecular
and biochemical analyses than primary cultured Schwann
cells. On the other hand, the degree of diﬀerentiation and
phenotypic expression of these Schwann cell lines diﬀer
from each other; continuous cell lines that possess distinct
phenotypes of mature Schwann cells are desirable for the
study of diabetic neuropathy. In this paper, we summarize
the biological features of these cell lines, especially IMS32
from adult ICR mice [21] and IFRS1 from adult Fischer
344 rats [22], and discuss their usefulness as in vitro models
of diabetic neuropathy. IMS32 cells seem to be one of
the best-characterized Schwann cell lines at present and
have advantages for the study of polyol pathway-related
abnormalities under diabetic conditions [23]. Although we
have limited information about IFRS1 cells at present, their
fundamental ability to myelinate axons in coculture with
adult dorsal root ganglion (DRG) neurons [22]w i l lb e
beneﬁcial for the study of neuron-Schwann cell interactions
under normal and diabetic conditions.
2.Immortalized AdultMouse Schwann
CellsIMS32
2.1. Establishment of Immortalized Schwann Cells. In the
primary cultures of DRG and peripheral nerves derived
from adult ICR mouse, their morphology and immunocy-
tochemical staining identiﬁed neurons, Schwann cells, and
ﬁbroblasts. These neurons were viable for at least 3 weeks
in vitro. Following repeated treatment of primary cultures
with antibody to mouse Thy-1.2 and rabbit complement
for the ﬁrst 2-3 weeks in vitro, the cultures consisted of
>95% Schwann cells and <5% ﬁbroblasts. These cells were
fed twice a week and passaged once in 2 weeks. After 6–
8 months in vitro, spontaneously developed colonies were
observed. They were separated using cloning rings, and ﬁve
diﬀerent cell lines (IMS8, 13, 26, 29, and 32) were obtained.
One of the cell lines, IMS32, was further characterized
[21]. Although the detailed mechanism of spontaneous
immortalization of these Schwann cells is still unknown,
it has been reported that rat Schwann cells can divide
indeﬁnitely under the appropriate culture conditions [24].
So far, we have been able to obtain immortalized Schwann
celllines frommice ofICR[19, 21],BALB/c[25],and C57BL
strains [26–29]( Table 1)and rats of Fischer 344 [22], Wistar,
and Sprague-Dawley strains (Watabe et al., unpublished
data). Taking these ﬁndings into consideration, it is likely
that the spontaneous immortalization of long-term cultured
Schwann cells is a general phenomenon in mice and rats,
regardless of their strains.
2.2. Biological Features of IMS32. IMS32 cells showed dis-
tinct Schwann cell phenotypes, such as the spindle-shaped
morphology (Figure 1(a)) and the expression of glial cell
markers (e.g., S100, glial ﬁbrillary acidic protein (GFAP)
(not shown), and p75 low-aﬃnity neurotrophin receptor
(p75NTR)( Figure 1(b)), transcription factors crucial for
Schwann cell development and peripheral myelin formation
(e.g., PAX3, Krox20, Oct6, and Sox10), and neurotrophic
factors required for the survival of neurons and the main-
tenance of neuron-Schwann cell interactions (e.g., nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), glial cell line-derived neurotrophic factor (GDNF),
and ciliary neurotrophic factor (CNTF)) [21, 25]. Similar
to primary and long-term cultured Schwann cells, IMS32
cells exhibit mitogenic responses to several growth factors
(e.g., platelet-derived growth factor BB homodimer (PDGF-
BB), acidic and basic ﬁbroblast growth factor (aFGF and
bFGF), and transforming growth factor (TGF)-β1, 2 [21]. In
contrast, IMS32 cells are diﬀerent from primary and long-
term cultured Schwann cells in that the former were not
contact inhibited and formed ball-shaped subcolonies when
cultures reached conﬂuence [21, 30]. We failed to show that
t h ec e l ll i n ec o u l dm y e l i n a t eam o u s ea x o n ,i nt h es a m e
way as endogenous Schwann cells in the peripheral nerves
and primary cultured Schwann cells (data not shown). We
speculate that the high proliferative activity of IMS32 cells
might impede continuous and stable neuron-Schwann cell
interactions, which usually take 4 weeks or longer to form
myelin sheath. In spite of those diﬀerences from normal
Schwann cells, IMS32 cells have been utilized to investigate
the action mechanisms of various molecules involved in
peripheral nerve regeneration (e.g., CNTF [31, 32], sonic
hedgehog [33], and galectin-1 [30]) and the pathogenesis of
diabetic neuropathy, as described below.
2.3. IMS32 as a Valuable Tool for the Study of
Diabetic Neuropathy
2.3.1. Polyol Pathway. T h er o l eo fS c h w a n nc e l l si nd i a b e t i c
neuropathy is often discussed in relation to the polyol
pathway hyperactivity. Aldose reductase (AR), the ﬁrst
enzyme in the polyol pathway, is localized to Schwann cells
in the peripheral nerves [34] and the increased glucose ﬂux
into the pathway via AR and the subsequent accumulation
of sorbitol in Schwann cells can directly or indirectly aﬀect
nerve functions [3, 6]. A cell line from rat Schwannoma,
JS1 [17], and primary cultured adult rat Schwann cells
[16] have been introduced to study polyol metabolism;
however, these cells did not display intracellular sorbitol
accumulationorenhancedARexpressionunderhighglucose
(25–30mM) conditions unless hyperosmotic stress (greater
than 100mM) was applied. In contrast to those studies,
we observed increased AR mRNA/protein expression and
marked accumulation of sorbitol and fructose in IMS32
cells cultured under a high glucose (30mM) condition.
Further, application of an AR inhibitor, ﬁdarestat (Sanwa
Kagaku Kenkyusho, Nagoya, Japan), to the high glucose
medium diminished the intracellular sorbitol content to a
level close to a normal (5.6mM) glucose medium [23, 35]
(Figure 2). These ﬁndings led us to believe that the culture
of IMS32 under high glucose conditions is a suitable in vitro
model for the study of polyol pathway-related abnormalitiesExperimental Diabetes Research 3
Table 1: Immortalized adult mouse Schwann cell lines established at the authors’ institutions.
Line Origin (murine disease model) Mouse strain Ref. no.
MS1 Wild-type ICR [19]
IMS32 Wild-type ICR [21, 25]
SPMS9 spm/spm (Niemann-Pick disease type C) C57BL/KsJ [26]
573C10 npcnih/npcnih (Niemann-Pick disease type C) BALB/c [25]
TwS1 Twitcher (globoid cell leukodystrophy (Krabbe)) C57/BL6J [27]
675C20 P0−/− (Charcot-Marie-Tooth disease type 1B) C57/BL6 [25]
654C1 NﬂFcr/+ (Neuroﬁbromatosis type I) C57/BL6J [25]
1113C1 Hexb−/− (GM2 gangliosidosis (Sandhoﬀ)) C57/BL6 [28]
1089C1 α-Gal A (−/0) (Fabry disease) C57/BL6 [29]
All the Schwann cell lines except MS1 (cells transfected by SV40 large T antigen gene) were established by spontaneous immortalization.
50μm
(a)
25μm
(b)
Figure 1: IMS32 showed distinct Schwann cell phenotypes such as spindle-shaped morphology (a) and immunoreactivity to p75NTR (b).
in diabetes. It remains to be elucidated why an increase
in the glucose concentration to 20–30mM, corresponding
to the plasma level in poorly controlled diabetic patients,
accelerated the polyol pathway in IMS32 [23, 35]b u tn o ti n
other cultured Schwann cells [16, 17]. Sorbitol is converted
to fructose by sorbitol dehydrogenase (SDH), the second
enzymeinthepolyolpathway.ThemRNAexpressionofSDH
in the primary cultured Schwann cells was much lower than
that of AR and was not upregulated by exposure to a 30mM
glucose condition [36]. In addition, treatment with an SDH
inhibitor, SDI-158, had no eﬀect on the intracellular sorbitol
levels [16]. On the other hand, the extracellular sorbitol
level in that condition was increased signiﬁcantly compared
with that in a 5.6mM glucose condition [16]. These ﬁndings
suggest that sorbitol is released from the cells into the media
by an unidentiﬁed transport mechanism under normal and
high glucose environments. It is of interest to note that
treatment with SDH inhibitors augmented accumulation
of sorbitol in the primary cultured Schwann cells and JS1
cells exposed to hyperosmotic conditions [16, 18]; SDH, as
well as AR, might function as a protective molecule against
osmotic stress. In contrast to those cells, the upregulation
of the mRNA expression for AR and SDH, together with
conspicuous increases of intracellular sorbitol and fructose
levels, was observed in IMS32 undera 30mM glucose condi-
tion [23]. It seems possible that IMS32 cells possess a much
highercapacitythanotherSchwanncellstostoresorbitoland
other glucose-derived metabolites. It is also noteworthy that
immortalized Schwann cells were established from not only
normal adultmice,butalsofrommouse modelsoflysosomal
storage diseases such as Niemann-Pick disease type C (NPC)
[25, 26], globoid cell leukodystrophy (Twitcher) [27], GM2
gangliosidosis (Sandhoﬀ disease) [28], and Fabry disease
[29].Thecellsoriginatedfromthosemousemodelswereable
to survive and proliferate in culture despite the progressive
accumulation of undergraded substrates in the cytoplasm.
2.3.2. Glycation. In addition to the polyol pathway hyperac-
tivity, nonenzymatic glycation of structural and functional
proteins in the peripheral nervous system is another impor-
tant cause of diabetic neuropathy. Research suggests that
advanced glycation end products- (AGEs-) induced modiﬁ-
cation of myelin proteins, cytoskeletal proteins, and extra-
cellular matrix proteins contributes to segmental demyelina-
tion, axonal degeneration, and impaired axoplasmic trans-
port and regenerative activity [37]. The receptor for AGE
(RAGE)islocalizedtoaxonsandSchwanncellsintheperiph-
eral nervoussystem [38], and AGE-RAGEinteractions under
diabetic conditions are involved in Schwann cell dysfunction
through activating several signaling pathways (e.g., NF-κB
and PKCβII pathways) [37–39]. RAGE is also known to
have multiple ligands besides AGEs (e.g., serum amyloid
A (SAA), S100/calgranulins, and high mobility group box-
1( H M G B 1 ) )[ 40], and their interactions may alter the4 Experimental Diabetes Research
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Figure 2: Intracellular contents of sorbitol (a) and fructose (b) in
IMS32 cells after 7 days of exposure to normal (Glc 5.6mM) and
high glucose conditions (Glc 30mM) in the presence or absence of
anARinhibitor,ﬁdarestat(1μM).Valuesrepresentthemean+SEM
of6experiments. ∗P<. 01ascomparedwith[Glc-5.6mM]or[Glc-
30mM/ﬁdarestat 1μM] (modiﬁed from [21]).
functional properties of Schwann cells [41, 42]. Our DNA
microarray and RT-PCR analyses revealed high glucose-
induced upregulation of SAA3 mRNA in IMS32 cells [23],
but its relevance to glycation or other neurodegenerative
changes remains unknown.
It is also important to note that some AGE precursors,
such as methylglyoxal (MG) and 3-deoxyglucosone (3DG),
are generated via the polyol pathway [43]. Thus, enhanced
glucose ﬂux into the polyol pathway can be a cause of excess
f o r m a t i o no fM Ga n d3 D G ,w h i c hi nt u r na c c e l e r a t e st h e
formation of AGEs and reactive oxygen species (ROS).These
compounds, when applied exogenously, exhibited potent
cytotoxicity to primary cultured neurons [44]a n dS c h w a n n
cells [45], and IMS32 cells [35, 46]. MG has been shown to
activate caspase-3 and c-Jun-N-terminal kinase (JNK) and
enhanced intracellular ROS formation in IMS32 cells [46].
2.3.3. Oxidative Stress. We observed the upregulation of
the oxidative stress markers, such as 4-hydroxy-2-nonenal
(4HNE), acrolein (ACR), and hexanoyl lysine (HEL), in
IMS32 under high glucose conditions [35]. 4HNE, one of
the 4-hydroxyalkenals generated from hydroxyperoxides, can
bind to histidine, lysine, and cysteine residues of various
proteins, thereby altering the protein structure and function.
In a recent study by Akude et al. [47], 4HNE leads to the
modiﬁcation of key mitochondrial proteins through adduct
formation and impairs mitochondrial function and axonal
outgrowth in adult DRG neurons. ACR is more reactive
than 4HNE and has exerted direct neurotoxic activities
on cultured hippocampal neurons, aﬀecting mitochondria
[48]. The induction of ACR in the retina [49]a n dk i d n e y
[50] under diabetic state suggests its involvement in the
development and/or progression of diabetic complications.
HEL, a novel lipid hydroperoxide-modiﬁed lysine residue,
is thought to be a useful biomarker for the initial stage of
lipid peroxidation [51]. The urinary HEL from patients with
diabetes was signiﬁcantly higher than that from nondiabetics
[52]. In addition, the HEL levels in the vitreous ﬂuid and
serum were signiﬁcantly higher in patients with proliferative
diabetic retinopathy than those in nondiabetic patients
(Macular hole) [53]. These ﬁndings suggest the involvement
of4HNE,ACR,and HELin thepathogenesisofdiabeticneu-
ropathy and/or other complications. In our study, exposure
to high glucose environments can accelerate the reactions
of lipid peroxidation and the production of the oxidative
stress markers in Schwann cells [35]. Oxidative damage
induced by mitochondrial dysfunction under hyperglycemic
conditions may trigger the apoptotic cascade [54]; however,
it is controversial whether hyperglycemia is a potent inducer
of apoptosis in cultured Schwann cells [55, 56]. We failed
to observe high glucose- (30mM and 56mM) induced
apoptosis of IMS32. These ﬁndings, together with those in
ap r e v i o u ss t u d y[ 56], suggest that the load of high glucose
on Schwann cells does not appear to be a suﬃcient inducer
of cell death unless subjected to further insults [57]. It is
noteworthy that ischemia-reperfusion injury to peripheral
nerves of STZ-diabetic rats caused a marked increase in
apoptotic Schwann cells [58]. A recent study by Padilla et al.
[59] indicate that palmitic acid- (PA-) induced lipotoxicity
accelerates the apoptotic cascade in immortalized adult
rat Schwann cells [20] under normal and high glucose
conditions; the lipotoxic eﬀect is more prominent in the
culture under high glucose conditions. Consistent with that
study, Suzuki et al. [60] observed the PA-induced apoptosis
in primary cultured Schwann cells and IMS32 cells under
normal glucose (5.5mM) conditions. According to those
reports, ER stress combined with oxidative stress might be
involved in the lipotoxicity in Schwann cells.
2.3.4. Synthesis of Neurotrophic Factors. NGF and the related
members of neurotrophin (NT) family (BDNF, NT-3, and
NT-4/5) are produced in target tissues of the peripheral
nervous system and transported retrogradely to the neuronal
perikarya, where they exert their actions [61]. Reduced
supply of NGF to the sensory and sympathetic neurons can
be a cause of small sensory and autonomic ﬁber dysfunction,
whereas deﬁciency of NT-3 appears to be involved in largeExperimental Diabetes Research 5
50μm
(a)
50μm
(b)
50μm
(c)
0.2μm
(d)
Figure 3: IFRS1 showed distinct Schwann cell phenotypes such as spindle-shaped morphology (a), immunoreactivity to vimentin (b), and
myelinationincoculture withadultratDRG neurons(c,d).After 3daysofcoculture (c),DRGneurons(arrows)andIFRS1cells areobserved
under a phase-contrast microscope. After 28 days of coculture (d), myelin formation is illustrated by electron microscopy.
ﬁ b e rd y s f u n c t i o ni nd i a b e t i cn e u r o p a t h y[ 62]. In addition,
deﬁcientsupplyofthesemoleculesunderdiabeticconditions
is associated with impaired axonal regeneration after injury
[63]. A few studies suggestedreduced synthesis and secretion
of these molecules in primary cultured Schwann cells under
diabetic conditions [64, 65], but its precise mechanisms
remain unclear.
According to a recent study by Tosaki et al. [66], condi-
tioned medium (CM) obtained from IMS32 under the high
glucose condition (30mM) showed lower NGF concentra-
tionandneurite-outgrowthactivityforculturedadultmouse
DRG neurons than that under the normal glucose condition
(5.5mM). These ﬁndings imply that the reduced NGF syn-
thesis by Schwann cells under hyperglycemic conditions can
be a cause of impaired axonal regeneration and dysfunction
of small-ﬁber sensory and autonomic ﬁbers [67]. However,
our DNA microarray analysis failed to show signiﬁcant
downregulation of mRNA expression for NGF and other
neurotrophicfactorsinIMS32underhighglucoseconditions
[23]. In addition, our previous study employing PC12 cells
revealed that the neurite outgrowth activity of NGF, but
not CM from IMS32, was attenuated by cotreatment with
anti-NGF neutralizing antibody [21]. These ﬁndings suggest
the combined eﬀects of multiple neurotrophic factors, other
than NGF, in case of CM. The quality and quantity of
neurotrophic molecules secreted from IMS32 cells under
hyperglycemicand/orhyperlipidemicconditionswill needto
be evaluated more precisely in the future study.
3.Immortalized SchwannCellsfrom
Murine Disease Models
Establishment of the Schwann cell lines from murine disease
models may greatly facilitate the studies of the cellular
mechanisms of their PNS lesions in the relevant diseases.
Besides Schwann cell lines derived from normal (wild-
type) mice, we have established spontaneously immortalized
mouse Schwann cell lines from murine models of NPC
[25, 26], Krabbe disease [27], Charcot-Marie-Tooth disease
[25], neuroﬁbromatosis [25], Sandhoﬀ disease [28], and
Fabry disease [29]( Table 1). These cell lines retain genomic
and biochemical abnormalities, suﬃciently representing the
pathological features of the mutant mice. In a similar
manner, we plan to establish immortalized Schwann cells
from AR-deﬁcient mice [68], RAGE-deﬁcient mice [69],
and the murine models of type 2 diabetes (e.g., db/db [70]
and ob/ob [71]). In addition to IMS32 cells, those cell
lines would provide useful information about the respective
pathogenetic mechanisms and their crosstalks leading to
diabetic neuropathy and the novel therapeutic approaches
against that condition.6 Experimental Diabetes Research
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Figure 4: Expression ofgalectin-3 (GAL-3) in IFRS1 cells after 7 days ofexposure to normal(Glc 5.6mM) and high glucose conditions (Glc
30mM). (a) Western blot analysis; the representative picture of the blot (upper) and quantitative data (lower) are shown. Values represent
themean+SEMof3experiments. ∗P<. 01ascompared with[Glc-5.6mM].(b) ImmunocytochemicallocalizationofGAL-3 inIFRS1cells.
The photomicrographs show more intense immunoreactivity for GAL-3 in [Glc 30mM] than that in [Glc-5.6mM].
4.ImmortalizedAdultRatSchwannCellsIFRS1
We have established immortalized Schwann cells from adult
Fischer 344 rats in a similar manner to the mouse cell lines
with slight modiﬁcations [22]. One of these cell lines, desig-
nated IFRS1, showed distinct Schwann cell phenotypes, such
as the spindle-shaped morphology (Figure 3(a)) and intense
immunoreactivity for S100, p75 NTR, GFAP, laminin (not
shown), and vimentin (Figure 3(b)). IFRS1 cells expressed
transcription factors (Krox20, Oct6, and SOX10)and myelin
proteins (P0, PMP22, and MAG) crucial for Schwann cell
development and peripheral myelin formation, in addi-
tion to neurotrophic factors (NGF, GDNF, and CNTF),
neurotrophin receptors (truncated TrkB, TrkC), and cell
adhesion molecules (L1, NCAM, and N-cadherin) required
for the survival and neurite outgrowth of neurons and the
maintenance of neuron-Schwann cell interactions. In con-
trast to IMS32 cells, growth stimulants such as neuregulin-β
andforskolin areneededforthegrowthandpassage ofIFRS1
cells. To investigate the ability of IFRS1 cells to myelinate
neurites, we cocultured IFRS1 cells with adult rat DRG
neurons in the serum-free medium (F12/B27)supplemented
with 50μg/mL ascorbic acid and 10ng/mL GDNF [72]
(Figure 3(c)). In this coculture system, excess proliferation
of IFRS1 cells was prevented by the absence of exogenous
neuregulin-β and forskolin. In addition, neuroprotective
molecules secreted from IFRS1 cells helped the cocultured
DRG neurons to survive for up to 4 weeks in serum-free
conditions. After 28 days of coculture, myelin formation was
illustrated by light and electron microscopy (Figure 3(d)).
These ﬁndings suggest that IFRS1 cells retain the character-
istic features of mature Schwann cells and the fundamental
ability to myelinate axons, thereby being a valuable tool for
exploring neuron-Schwann cell interactions.
It remains to be elucidated if IFRS1 cells and/or DRG
neurons/IFRS1 cell cocultured system under hyperglycemic
and/or hyperlipidemic conditions can be a suitable model
for the study of diabetic neuropathy. Unlike IMS32 cells,
neither AR expression nor intracellular polyol levels were
enhanced by exposure of IFRS1 cells to a high glucose
(30mM) condition (Sango et al., unpublished data). How-
ever,ourpreliminary studyshowedthehighglucose-induced
upregulation of galectin-3 (GAL-3) in IFRS1 cells (Figure 4).
GAL-3 is a member of a family of β-galactoside-binding
animal lectin and regulates cell-to-cell and cell-to-matrix
interactions. Like RAGE, p60 (AGE-R1), and p90 (AGE-
R2), GAL-3 is identiﬁed as an AGE-binding protein [73].
Aragno et al. [74] reported that the upregulation of RAGEExperimental Diabetes Research 7
and GAL-3 in the hippocampus of STZ-diabetic rats was
inhibited by treatment with antioxidants. Also, it is of
interest to note that exogenous GAL-3 inhibits proliferation
of Schwann cells in cultured sciatic nerve segments [75].
Consistent with this ﬁnding, GAL-3 knockout mice show
earlier functional recovery and faster regeneration after
sciatic nerve crush than the wild-type animals [76]. Further
studies are needed to determine whether the upregulation of
GAL-3inSchwanncellsunderdiabeticconditionsisinvolved
in the pathogenesis of diabetic neuropathy such as glycation,
oxidative stress, and reduced regenerative capability.
5.Conclusion
The spontaneously immortalized Schwann cell lines, such
as IMS32 and IFRS1, retain the characteristic features of
mature Schwann cells. Considering that an increase in
glucose concentration to 20–30mM accelerated the polyol
pathway in IMS32 cells, but not in other Schwann cells, the
culture system of IMS32 under high glucose conditions may
provide useful mechanistic information about the pathogen-
esis of diabetic neuropathy, especially polyol pathway-related
abnormalities.IFRS1cellsarecapableofmyelinatingneurites
in coculture with DRG neurons, and this coculture model
can be a valuable tool for exploring neuron-Schwann cell
interactions under normal and diabetic conditions.
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